Dai-ichi Life Insurance, Essential Pharma and Medi-Future were among the investors in a round that brought the pre-clinical drug developer's funding haul to $33.1m.
Japan-based drug developer Modulus Discovery completed a ¥2.7bn ($25.2m) series B round yesterday featuring life insurer Dai-ichi Life Insurance, drug manufacturer Essential Pharma and women’s healthcare company Medi-Future.
SBI Investment, Mizuho Capital and SMBC Venture Capital – investing on behalf of financial services firms SBI Holdings, Mizuho Bank and Sumitomo Mitsui Banking Corporation – also participated, as did UTokyo Innovation Platform and Keio Innovation Initiative, investing for University of Tokyo and Keio University, respectively.
Jafco, Fast Track Initiative and Mobile…
